Your Account
close button

Use our patient tools for secure, convenient, 24/7 access. Learn more

OR

This facility is a member of


Connect with us:

Breast Cancer

   

A Randomized Phase III Trial of the Value of Early Local Treatment for the Intact Primary Tumor in Patients with Metastatic Breast Cancer [ECOG 2108]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.

A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer [NSABP B-49]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.

Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity [WFU 97609]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.

Receptor-Positive

A Randomized Phase III Double-Blind, Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without  Bevacizumab for patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer [ECOG 1105]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.

Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less [SWOG 1007]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.

 

Share